Marinus (MRNS) Plans Conference Call to Reports Results From Phase 2 Study of Ganaxolone in Children with Fragile X
Tweet Send to a Friend
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
